In this free webinar, learn how advanced cell line development can help accelerate the transition from drug discovery to first-in-human studies and scalable manufacturing. The featured speaker will discuss how targeted gene integration using a transposase with epigenetic targeting can establish productive, stable cell pools early in development. Attendees will also explore how automated clone screening can prioritize product quality and upstream process compatibility when selecting high-performing producer clones.
TORONTO, Nov. 19, 2026 /PRNewswire/ -- An efficient transition from drug discovery to first-in-human studies requires highly productive clones with the right product quality and scalable processes for rapid process development toward robust GMP manufacturing. Getting cell line development right from the start lays the foundation for the development path ahead.
This webinar explores how a unique expression platform, together with complementary tools and technologies, can make a difference in cell line development, from efficient gene integration and high-performing stable pools to smart automation for quality-driven selection of producer clones.
Applying a transposase that uses epigenetic targeting to integrate genes at the most active genomic sites yields bulk pools with high, stable titers and consistent product quality. These pools enable rapid material supply for development activities and toxicology studies. The impact on clone selection is even greater: with productivity and expression stability secured early, the focus of clone screening can shift towards product quality and process performance.
Assessing product quality across large numbers of clones remains a critical challenge. However, with the right approach, this challenge turns into an opportunity to select even better clones. A Smart Automation Solution enables earlier screening of large clone panels to assess compatibility with upstream processing (USP) platforms and critical product quality attributes. This combination of smart automation and advanced product characterization supports delivery of high-quality producer clones in a shorter timeframe, facilitating scalable manufacturing and rapid progression towards first-in-human studies.
Register for this webinar to learn how advanced cell line development can help pave the path to scalable manufacturing and successful first-in-human studies.
Join Thomas Rose, PhD, Director of Expression Systems, ProBioGen, for the live webinar on Wednesday, December 9, 2026, at 11am EST (5pm CET / EU-Central).
For more information, or to register for this event, visit Smarter Cell Line Development for First-in-Human Success: Building Better Clones.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]
SOURCE Xtalks


Share this article